Logo

IASO Bio Reports the US FDA’s IND Approval of Equecabtagene Autoleucel for Two New Autoimmune Diseases

Share this

IASO Bio Reports the US FDA’s IND Approval of Equecabtagene Autoleucel for Two New Autoimmune Diseases

  • The US FDA has cleared the IND application of Equecabtagene Autoleucel (Eque-cel) as a treatment of non-renal systemic lupus erythematosus (SLE) & lupus nephritis (LN) 

  • Eque-cel has previously obtained 3 IND approvals from the US FDA for autoimmune conditions (MG, MS, SLE/LN) & 2 from the NMPA for NMOSD & MG. It was also approved by the NMPA in Jun 2023 to treat r/r multiple myeloma after multiple prior therapies 

  • Eque-cel is a BCMA-targeted CAR T-cell therapy developed to eliminate BCMA-expressing cells. It reduces pathogenic cells & autoantibodies in SLE patients, suppressing autoimmune inflammation. Studies in China have shown its efficacy & safety in treating r/r autoantibody-mediated neurological diseases ia

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions